AZ's Lynparza Shines Again In Prostate Cancer Study

PARP Inhibitor Improves Overall Survival

 
• By Kevin Grogan

With a PDUFA date fast approaching, AstraZeneca has presented more data from the PROfound study, this time showing that Lynparza improved OS compared to hormonal therapies in men with advanced castration-resistant prostate cancer with BRCA1/2 or ATM mutations.

Jigsaw_Pieces
If approved, prostate cancer would be the fourth indication for Lynparza • Source: Shutterstock

More from Anticancer

More from Therapy Areas